Your browser doesn't support javascript.
loading
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew.
  • Gordon KB; Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: kegordon@mcw.edu.
  • Foley P; Skin Health Institute, Carlton, and The University of Melbourne, Parkville, VIC, Australia.
  • Krueger JG; The Rockefeller University, New York, NY, USA.
  • Pinter A; Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
  • Reich K; Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Vender R; Division of Dermatology, McMaster University, Hamilton, ON, Canada.
  • Vanvoorden V; UCB Pharma, Brussels, Belgium.
  • Madden C; UCB Pharma, Raleigh, NC, USA.
  • White K; UCB Pharma, Berkshire, UK.
  • Cioffi C; UCB Pharma, Raleigh, NC, USA.
  • Blauvelt A; Oregon Medical Research Center, Portland, OR, USA.
Lancet ; 397(10273): 475-486, 2021 02 06.
Article en En | MEDLINE | ID: mdl-33549192
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article